Table 1.
Clinical characteristics of APCA-negative and APCA-positive patients with HT (n=840).
| Characteristics | All patients (n = 840) | APCA negative (n = 660) | APCA positive (n = 180) | p value* |
|---|---|---|---|---|
| Mean age (years) | 50.1±14.5 | 49.0±14.6 | 54.1±13.5 | <0.001 |
| Gender (female) | 693 (82.5%) | 550 (83.3%) | 143 (79.4%) | 0.268 |
| TPO antibodies | 717/835 (85.9%) | 503 (83.9%) | 156 (93.3%) | 0.001 |
| Tg antibodies | 578/824 (70.1%) | 454 (70.2%) | 124 (70.1%) | 1.000 |
| Coexistence of other autoimmune diseases | 140 (16.7%) | 104 (15.8%) | 36 (20.0%) | 0.214 |
| no (thyroid only) | 700 (83.3%) | 556 (84.2%) | 144 (80%) | 0.024 |
| Organ-specific autoimmunity | 79 (9.4%) | 53 (8%) | 26 (14.4%) | |
| Systemic autoimmunity | 61 (7.3%) | 51 (7.7%) | 10 (5.6%) | |
| Family history for thyroid autoimmunity | 461/835 (55.2%) | 361 (54.9%) | 100 (56.2%) | 0.799 |
| Malignancy | 85 (10.1%) | 63 (9.5%) | 22 (12.2%) | 0.328 |
| PTC | 29 (3.5%) | 20 (3.0%) | 9 (5.0%) | 0.246 |
| GNEN | 4 (0.5%) | 0 | 4 (2.2%) | <0.001 |
| Gastric Ca | 1 (0.1%) | 0 | 1 (0.6%) | |
| Breast Ca | 21 (3%#) | 19 (3.5%#) | 2 (1.4%#) | 0.196 |
| Other | 30 (3.6%) | 24 (3.6%) | 6 (3.3%) |
*P value refers to comparisons between APCA-negative and APCA-positive patients; #among women computed; APCA, anti-parietal cell antibodies; TPO, thyroid peroxidase; Tg, thyroglobulin, PTC, papillary thyroid carcinoma; GNEN, gastric neuroendocrine neoplasm; Ca, carcinoma. Bold values denote statistical significance at the p<0.05 level.